RESEARCH ARTICLE

Experimental and Theoretical Investigation of 3D-Metal Complexes Derived from *N*-(1*H*-**Benzimidazol-2-yl)-2-mercaptoacetamide Derivative**

NEELAMMA.M^{1*}, G.H. ANURADHA², S. SREEKANTH¹ and B. MANOGNA³

¹Department of Chemistry, University College of Science, Osmania University, Hyderabad-500004, Telangana, India

²Department of Chemistry, Sardarpatel College, Padmarao Nagar, Secunderabad-500025, Telangana, India

³Anurag Group of Institutions, Venkatapur, Ghatkesar, Medchal (Dist), Hyderabad- 500088, Telangana, India

nbudarapu@gmail.com

Received 29 November 2018 / Accepted 23 December 2018

Abstract: New trinuclear metal complexes of Co(II), Ni(II), Cu(II) and Zn(II) with *N*-(1*H*-benzimidazol-2-yl)-2-mercaptoacetamide (BMA) were synthesized from chloride salts of relative metals in butanol medium. Synthesized metal complexes were characterized by elemental analysis, conductance measurements, IR, UV-Vis, ESR, TGA & DTA and magnetic susceptibility measurements. IR spectral data suggest that the ligand behaves as monobasic tridentate (NOS) with donor sites of azomethine nitrogen (ring), oxygen atom of carbonyl group and thio group. Physico-chemical data suggest tetrahedral geometry for Co(II), Ni(II) and Zn(II) complexes. Square planar intended for Cu(II) complex and all these complexes exhibits non-elecrolytic nature. The complexes were evaluated for their antimicrobial activity by *in-vitro* antimicrobial screening against bacteria *Staphylococcus aureus, Bacillus subtilis, Escherichia coli* and *Klebsiella Pneumonia*. The results indicate that antimicrobial activity increased during metallation. A detailed analysis is done theoretically using DFT method with B3LYP/6-311G/LanL2DZ functional for ligand and complexes. Docking studies of ligand and metal complexes carried out using OPLS 2005 force field in Schrodinger suite.

Keywords: Metal complexes, DFT method, antibacterial, docking studies.

Introduction

Benzimidazole moiety is a residue which leads most important role in building a variety of biologically active molecules such as vitamin B_{12} , support their potential use as therapeutics.

This nucleus is very important pharmacophore in medicinal chemistry as well as in modern drug discovery. Benzimidazole is well known with its widespread applications as drugs, dyes, polymers and enzyme¹⁻³. Derivatives of benzimidazole exhibits additional applications in some areas as organic luminophores, fluorescent tags for detection of biological important molecules, as DNA, RNA or proteins and enzymes^{4,5}, as optical laser and polymer dyes in optoelectronics^{6,7} *etc.* 2-Substituted benzimidazole derivatives show anti-hypertensive activities⁸ and anti-influenza⁹. Amino benzimidazole derivatives are remarkable and are found in drugs as well as natural products¹⁰. Chelating ligands containing N, N, O and S donor atoms show broad biological activity and are of special interest because of the ways in which they are bonded to the metal ions¹¹. It is known that existence of metal ions bonded to biologically active compounds may enhance their activities^{12–14}. In view of importance of above, these two scaffolds are selected in the preparation of ligand using butanol medium.

Experimental

Metal salts and solvents used were E-Merck products. All other chemicals used were of AR grade. Elemental analysis was carried out using micro analytical techniques on Heraeus - CHN rapid analytical, metal estimations were done on a Perkin Elmer 2380 atomic absorption spectrometer. Conductivity measurements were carried on Elico digital conductivity meter model No.CM-180. The magnetic susceptibility measurements were done on a factory balance (CAHN-7600) using Hg [Co (SCN)₄] as calibrate. TGA, DTA data was established by using Leeds and Northrop-USA instrument. Infrared spectra were recorded on a Perkin-Elmer 1600. The electronic spectra were recorded on a Shimadzu UV-160 spectrophotometer. Thermal studies were carried out using Shimadzu TGA-50H in the nitrogen atmosphere. Metal salts and solvents are used E-Merck product All other chemicals used were Analar grade.

Synthesis of N-(1H-benzimidazol-2-yl)-2-mercaptoacetamide

2-Aminobenzimidazole (1.33g, 1.0 m.mol), thioglycollic acid ester (1 mL, 1.0 m.mol) were dissolved in n-butanol (10 mL) and mixture was refluxed 2-3 h, yellow coloured compound separates out on cooling and recrystallized from n-butanol. Yield: 75%, M.P: 215 °C.

The compound is stable to air and moisture. Its purity was checked with TLC using different solvent mixtures. BMA is crystalline and is soluble in common organic solvents like CH₃OH, CHCl₃ and acetone *etc*. BMA(C₉H₉N₃OS) yellow powder (Figure 1). Melting point: 215 °C; UV (EtOH) λ_{max} / nm = 249 nm, 293 nm and 425 nm; IR (diamond): v/cm⁻¹ = 3270, 3109, 1607, 1564, 2672, 691; 1H NMR (DMSO-d6, 300 MHz): δ /ppm = δ 2.1(s, 2H), δ 5.8 (broad s, 1H, NH _{Benz}), δ 7.2 (m,4H Ar); Anal. Calcd for C₉H₉N₃OS (207.25 gmmol⁻¹) (%): C, 52.16; H, 4.34; N, 20.28; S, 15.45; Found: C, 52.11; H, 4.36; N, 20.28; S, 15.40. Mass m/e: 173,160, 133,132,105, 90 (Figure 2).

Synthesis of transition metal complexes

N-(1H-Benzoimidazol-2-yl)-2-mercaptoacetamide (BMA) (0.21 g, 1 mmol) was added drop wise to solution of divalent metal chloride Co(II) (0.238 g), Ni(II) (0.237 g), Cu(II) (0.172 g) and Zn(II) (0.132 g) (1 m.mol) in 10 mL absolute methyl alcohol. The pH of the mixture was adjusted to 7 using 5% ammonia-CH₃OH mixtures and refluxed for 3-4 h complex which separated was filtered in hot condition, washed with a small portion of cold methanol and diethyl ether and dried in vacuum. The purity of metal complexes was tested by TLC using different solvent mixtures. Yield: 50-60%.



Figure 2. NMR spectra of BMA

All the metal complexes except Zn(II) are colored and stable to air and moisture. They decompose at high temperatures. They are soluble in DMF and DMSO and insoluble in common organic solvents like methanol, acetone and chloroform.

 $[CoLCl].5H_2O (1): Black, M.P. > 350 \ ^{\circ}C, yield 42\%, \mu_{eff}: 3.58BM. Anal. Calcd for C_9H_{18}N_3O_6SClCo (390.4g.mol^{-1}) (\%): C, 27.58; H 4.59; N, 10.72; S, 8.17. Found: C, 27.53; H, 4.57; N, 10.67; S 8.13. IR (selected bands, cm^{-1}): v(N-H) 3700-2900 br, v(C=N), v(C=O) merge 1583, v(C=S) 620. UV-Vis [\lambda_{max}, nm: 1180,818. Conductance (mho cm^2mol^{-1}) 35.$

[NiLCl].2H₂O (**2**): Brown, M.P. 314.0–315.6 °C, yield 39%, μ_{eff} : 3.92 BM. Anal. Calcd for C₉H₁₂N₃O₃SClNi (336.19 g mol⁻¹) (%): C, 32.02; H, 3.55; N, 12.45; S, 9.48%. Found: C,31.98; H, 3.53; N, 12.41; S, 9.47. IR (selected bands, cm⁻¹1): v(N-H) 3726-2792 br, v(C=N), v(C=O) merge 1584 v(C=S) 630. UV–Vis [λ_{max} , nm: 1126, 600. Conductance (mho cm²mol⁻¹) 28.

[CuLCl] (3): Dark green, M.P. > 350 °C, yield 73%, μ_{eff} : 1.98 BM. Anal. Calcd for C₉H₈N₃O₃SClCu(337.0 g mol⁻¹) (%): C, 36.28; H, 2.61; N, 13.72; S, 10.45%. Found: C, 35.22; H, 2.58; N, 13.69; S, 10.42. IR (selected bands, cm⁻¹): v(N-H) 3600-2700br, v(C=N) 1601, v(C=O) 1672 v(C=S) 617. UV–Vis [λ_{max} (log ϵ), nm: 640, 520.Conductance (mho cm²mol⁻¹) 40.

[ZnLCl] (4): Pale yellow, M.P. > 350 °C, yield 70%, μ_{eff} : Dia mag. Anal. Calcd for Zn(C₉H₈N₃O₃SCl (338.8 g mol⁻¹) (%): C, 35.12; H, 2.60; N, 13.65; S, 10.40%. Found: C, 35.08; H, 2.57; N, 13.62; S, 10.50. IR (selected bands, cm⁻¹): v(N-H) 3700-2800 br, v(C=N) 1572, v(C=O) 1630 v(C=S) 619. UV–Vis [λ_{max} , nm: 640, 520. Conductance (mho cm²mol⁻¹) 12.

Biological activity

Biological activity of complexes **1–4** was tested against gram positive bacteria, (*Staphylococcus aureus* and *Bacillus subtilis*) and gram negative bacteria (*Escherichia coli,* and *Klebsiella Pneumonia*) using Muller Hinton nutrient agar media by the well diffusion technique¹⁵. The results were recorded as zones of inhibition in mm and compared with the standard drug streptomycin for antibacterial activity.

Computational methods

Nowadays, computational methods based on density functional theory (DFT) have been widely used. The studies indicate that density-functional theory (DFT) is a powerful tool for predicting geometry and stability of the molecules¹⁶⁻¹⁹. A visual representation of the molecular geometry is obtained with the aid of the animation option of Gauss View 5.0 graphical interface²⁰. In order to understand the vibrational properties, structural characteristics of the ligand BMA and of complexes the density functional theory (DFT) method with B3LYP/6-311G the basis set while the metal atoms were optimized using LANL2DZ functional. To show the existence of intramolecular orbital (HOMO), lowest unoccupied molecular orbital (LUMO) levels and the molecular electrostatic potential (MEP) energy surface are studied.

Docking studies: Methodology

Ligand and metal complexes were constructed in ChemDraw and minimized using MM2 protocol. Crystal structure of DNA was downloaded from protein data bank (<u>www.rcsb.org</u>) pdb id: 1N37²¹, it was prepared by protein preparation wizard applying OPLS 2005 force field in Schrodinger suite 2010. The prepared DNA was imported into AutoDockTool²², binding site was defined around the bound crystal ligand and a grid was prepared using Autogrid4. The ligand and metal complexes were docked into the DNA major groove.

Results and Discussion

Characterization of the ligand (BMA)

The IR spectrum (Figure 3a) of BMA shows a peak at 3270 cm⁻¹ assigned to stretching vibration of free vNH. A band due to ringv NH vibration is observed at 3109 cm⁻¹. A band at 1607 and 1564 cm⁻¹ are ascribed to vC=O and ring vC=N respectively. A band at 2672 cm⁻¹ is assigned to vSH and 691cm⁻¹ is assigned to vC-S. The electronic spectrum (Figure b) of BMA shows absorptions at 249 nm, 293 nm and 425 nm. The high energy band at 249 nm is attributed to $\pi \rightarrow \pi^*$ transitions of benzimidazole. The band at 293nm is due to benzene moiety. The other band at 425 nm is assigned due to azomethine group.





Figure 3. Spectra of BMA (a) IR (b) Electronic and (c) Mass spectra

Characterization of the complexes

Elemental analysis shows that the metal to ligand ratio is 1:1 in all the complexes. The data suggests the presence of one chloride per divalent metal ions. The low molar conductance values of all the complexes in the range $21-40 \text{ mhocm}^2\text{mol}^{-1}$ at room temperature indicate non electrolytic nature of the metal complexes. Analytical and conductance data indicate that the ligand is behaving as a monobasic one.

Thermal analysis of BMA metal complexes

The data of Co(II) and Ni(II) complexes show endotherms relatively at lower temperature in the range of 90°C to 115 °C which can be attributed to crystal water. The endotherm is succeeded by an intense and broad exotherm in the range of 190 °C to 510 °C which may represent the completion of the decomposition.

IR spectra of BMA metal complexes

In all the complexes there is downward shift in vC=N and vC=O. In Co(II) and Ni(II) complexes the strong intense broad band observed at 1560 cm⁻¹ is assumed to arise due to merger of vC=O, vC=N. The IR spectra of the complexes provide evidence in support of the involvement of SH group in coordination. This indicated by the downward shift of vC-S. The vC-S band observed at 691cm⁻¹ in free ligand shows negative shift in complexes up to 617cm⁻¹as shown in Table 1. Disapperance of vS-H in complexes is evidence that 'S' coordinated with metal with dissociation of '-SH' proton. The spectra do not provide any confirmatory evidence regarding deprotonation of SH. IR spectra of the complexes are given in Figure 4 and data in Table 1. In Co(II) and Ni(II) complexes also the broad band located in the range of 3700 to 2700 cm⁻¹ is attributed to OH (H₂O) and NH. The non-ligand bands in the range of 655-460 cm⁻¹ are assigned to M-O, M-S and M-N²³ modes. The M-Cl bands are identified at 370-250 cm⁻¹. This is indicating that binding to the metal is through a NOS sequence involving the ring azomethine nitrogen, carbonyl oxygen and deprotonated thiolic group. The presence of chloride in complexes was identified by Volhard's test²⁴.

Lig/complexes	vNH	vC=N	vC=O	vC-S	vSH	New bonds
BMA	3109-3270	1564	1687	691	2672	
Co(II)complex	3700-2900	15 ←	83 →	620		883,695,560,490, 460,370,255
Ni(II)complex	3726-2792	15	84	630		890,702,630,469,
		←	→			435,330,270,250
Cu(II)complex	3600-2700	1601	1672	617		617,534,499,325, 270
				610		

Table 1. IR data of ligand and complexes



Figure 4. IR spectra of (a) Ni(II) and (b) Cu(II)-BMA complexes

Magnetic data of BMA complexes

The magnetic moment values of Co(II) and Ni(II) complexes are 3.58 and 3.92 B.M. respectively. In Cu(II) complex the magnetic moment value is 1.98 B.M. which corresponds to one unpaired electron.

Electronic spectra of BMA metal complexes

The absorption spectrum of Co(II) complex shows a high intensity band at 1180nm and medium intensity band at 818 nm. These bands are assigned to ${}^{4}A_{2} \rightarrow {}^{4}T_{1}$ (F) and ${}^{4}A_{2} \rightarrow {}^{4}T_{1}$ (P) transitions respectively tetrahedral geometry is proposed.

The absorption spectrum of Ni(II) complex shows a high intensity band at 1126 nm and medium intensity band at 600 nm. These bands are assigned to ${}^{3}T_{1} \rightarrow {}^{3}A_{2}$ and ${}^{3}T_{1}$ (P) transitions respectively. Tetrahedral geometry is proposed.

The absorption spectrum of Cu(II) complex shows a broad multiple band in the range of 640nm to 520 nm which can be assigned to a combination of three transitions from ${}^{2}B_{1}$ ground state to ${}^{2}B_{2}{}^{2}A_{1}{}^{2}E$ states. Square planar geometry is proposed.

ESR spectra of Cu (II)-BMA complex

The ESR spectrum of BMA-Cu(II) complex was recorded at room temperature and shown in the Figure 5. DPPH with a g value of 2.0036 was used as standard. The spectrum apparently consists of a single intense signal. The tendency of the g-tensor exhibiting isotropic behaviour. The g value evaluated from the spectrum ($g_{iso}2.043$) supports this isotropic nature. The reason for getting a single ESR spectrum may be due to the exchange coupling interactions among Cu(II) ions. However g value (2.043) indicates that the electron in the Cu(II) ion is largely delocalized. The A value is 130 G. Square planar geometry around Cu(II) is confirmed by other experimental data.



Figure 5. ESR spectra of Cu-BMA complex

Biological activity

Antimicrobial activity of the ligand L and its complexes 1–4 were tested against four pathogenic bacteria species by the well diffusion method (Table 2). The study indicated that the complexes 1–4 exhibited higher antimicrobial activity than the free ligand L and their activity depended upon the size and charge distribution of metal ions, shape and redox potential of the metal chelates²⁵. The complexes 3 and 4 were more potent than the other ones. The increased inhibition activity of complexes can be explained on the basis of the Overtone's concept and Tweedy's Chelation hypothesis²⁶. The observed zones of inhibition for the complexes 1–4 followed the order: control >3 > 4 > 1> 2 > L that matched the computational studies. This can be elucidated on the basis of Structure-Activity Relationship²⁷ (SAR). Complexes 1 and 2 are less active due to the low lipophilicity of M(II) ion and low penetration of these complexes through the lipid membrane.

Organism		Gram p	ositive			Gram n	egative	
Sample	Staphy au	lococcus reus	Bacillu	s subtilis	Escheri	chia coli	Kleb Pneu	siella monia
Concentration	1 mg/mL	0.5 mg/mL	1 mg/mL	0.5 mg/mL	1 mg/mL	0.5 mg/mL	1 mg/mL	0.5 mg/mL
BMA (L)	18	11	16	11	18	12	NA	NA
1. Co(II) complex	29	19	26	19	24	16	19	17
2.Ni(II) complex	24	14	19	15	21	15	16	13
3 .Cu(II) complex	43	28	39	29	39	26	28	21
4.Zn(II) complex	39	23	32	21	36	22	21	18
streptomycin	48.9	30.3	48.8	31.9	43.3	33	32.3	24.3

Table 2. Antibacterial activities of the ligand and its complexes 1-4 by the well diffusion method

Computational Studies

Frontier molecular orbital analysis

The HOMO and LUMO frontier orbital, determine the way the molecule interacts with other species. The HOMO is the orbital that primarily acts as an electron donor and LUMO is the orbital that largely acts as electron acceptor and the gap between HOMO and LUMO characterizes the stability and light on chemical reactivity of the molecule²⁸. The computed energy gap (ΔE) for the ligand BMA as well as the complexes given in Table 3 (Figure 6). The frontier orbital energy gaps of 1.6915-2.6468 eV in the complexes indicate d-d transitions and are in accordance with the eminent broad shoulder found from the electronic spectra.



Figure 6. HOMO, LUMO and ΔE of ligand and metal complexes

Molecular electrostatic potential (MEP) of ligand and its complexes

To predict reactive sites for electrophilic and nucleophilic attack for the title molecule, MEP maps were generated from the molecular orbital energies obtained from DFT calculations. The molecular electrostatic potential surface displays molecular shape, size and electrostatic potential values of (BMA) and its complex. The molecular electrostatic potential (MEP) surface diagram is related to the electronic density and is a very useful descriptor in understanding sites for electrophilic attack and nucleophilic reactions as well as hydrogenbonding interactions²⁹⁻³¹. The negative regions can be regarded as nucleophilic centers, and

the positive regions as potential electrophilic sites in the electrostatic potential map (Figure 7). The hydrogen atoms in ligand BMA and in case of the complex bear the maximum positive charge. The predominance of green region in the MEP surface corresponds to an electron density distribution in between the two extremes red and dark blue color.



Figure 7. HOMO, LUMO, MEP surface density diagrams of ligand and its complexes.

Reactivity descriptors

The highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) are very important parameters for quantum chemistry. The frontier orbital energy gap helps to distinguish the chemical reactivity and kinetic stability of compounds. Nicomplex is more polarizable due to a small frontier orbital energy gap. This complex is normally associated with a high chemical reactivity termed as soft with low kinetic stability.

The chemical potential (μ), global hardness (η) and electrophilicity (w) are global descriptors which indicate the overall stability of a chemical system. Order of stability is Ligand> Cu(II)>Zn(II)>Co(II)>Ni(II). Complexes are the more reactive than ligand with the

lower value of chemical hardness. Hence, the ligand exhibit their greatest affinity toward the Ni(II) ion and the least toward the Cu(II) ion. The values of some global reactivity descriptors³²⁻³⁴ investigated are presented in Table 3.

Table 3. DFT- 6-311G Basis set Calculation Summary for ΔE , absolute electronegativity (χ_{abs}), absolute hardness (η), electrophilicity index (ω), global softness (s) of the ligand and its complexes

Lig/com	HOMO	LUMO	ΔΕ	$\chi_{abs} = -u$	η	$\omega = u^2/2n$	S=1/ η
BMA	-6.2061	-1.7778	4.4283	-3.9919	2.2141	3.5985	0.4516
Co(II)	-5.6733	-3.4077	2.2656	-4.5405	1.1328	9.0995	0.8827
Ni(II)	-5.4273	-3.7358	1.6915	-4.5815	0.8457	12.4094	1.1823
Cu(II)	-5.9786	-3.3318	2.6468	-4.6552	1.3234	8.1873	0.7556
Zn(II)	-5.7881	-3.4752	2.3129	-4.6316	1.1564	9.2747	0.8646

Docking studies

Methodology

Ligand and metal complexes were constructed in ChemDraw and minimized using MM2 protocol. Crystal structure of DNA was downloaded from protein data bank (www.rcsb.org) pdb id: 1N37³⁵, it was prepared by protein preparation wizard applying OPLS 2005 force field in Schrodinger suite 2010. The prepared DNA was imported into Auto Dock Tool³⁶, binding site was defined around the bound crystal ligand and a grid was prepared using Autogrid4. The ligand and metal complexes were docked into the DNA major groove. Based on the present studies it may be concluded that the ligand exhibit promising antibacterial activity and activities can be subjected to change through metallation. The dock score and inhibition constant values (Table 4) which are the parameters to determine binding affinity conclude that metal complexes have better binding affinity than free ligand BMA

Table 4. Dock score and inhibition constant of ligand and complexes

Complex	Dock score	Estimated Inhibition		
Complex	(kcal/mol)	Constant (Ki in µM)		
BMA	-4.97	227.88		
Co(II) complex	-5.59	79.94		
Ni(II) complex	-5.35	119.92		
Cu(II) complex	-5.98	41.32		
Zn(II) complex	-5.63	75.30		



Figure 8. Dock pose of ligand in the major grove of DNA showing hydrogen bond interaction with G13 and π - π interaction with T14, G13 and G5

As per docking studies all the metal complexes showed better binding than Ligand, clearly indicating the importance of metal chelation. Copper complex is better in terms of docking studies.



Figure 9. Dock pose of Cu-Complex in the major grove of DNA showing hydrogen bond interaction [green lines] with T14 and G5

The greater binding affinity of complexes is due to the formation of hydrogen bond with G13 (Figures 8-11) and $\pi -\pi$ interaction with [pink lines] with T14 and G5. Cu(II) complex showed more negative dock score of followed by Zn(II), Co(II) and Ni(II) complexes. The higher binding affinity of Cu-Complex is due to the increase in hydrogen bond interaction than the ligand.



Figure 10. Dock pose of Ni-Complex in the major grove of DNA showing hydrogen bond interaction with G5. Complex also has π - π interaction with T14, C4 and G5



Figure 11. Dock pose of Zn-Complex in the major grove of DNA showing hydrogen bond interaction with G5. Complex also has π - π interaction with T14, G13 and G5

Conclusion

BMA is behaving as a monobasic tridentate system employing the ring azomethine nitrogen carbonyl oxygen, and deprotonated thiolic group thus providing an NOS sequence. All the complexes are homonuclear and are forming 1:1complexes. Based on analytical, thermal, conductivity, magnetic and spectral data tetrahedral geometry have been proposed to Co(II), Ni(II) and Zn(II) complexes. Square planar for Cu(II) complex. Theoretical data reveal that there is a concord with microbial activity of complexes. On coordination of metal complexes enhances the activity than the ligand. The proposed structures are given in the Figure 12.



Figure 12. Tentative structures of Metal complexes

References

- 1. Yadav G and Ganguly S, *Eur J Med Chem.*, 2015, **97**, 419-443; DOI:10.1016/j.ejmech.2014.11.053
- Bansal Y and Silakari O, *Bioorg Med Chem.*, 2012, 20(21), 6208-6236; DOI:10.1016/j.bmc.2012.09.013
- 3. Wang T, Zhao Z, Wei B, Zhang L and Ji L, *J Mol Struct.*, 2010, **970**, 128-133. DOI:10.1016/j.molstruc.2010.02.061
- 4. Hranjec M, Pavlovic G, Marjanovic M, Kralj M and Karminski-Zamola G, *Eur J Med Chem.*, 2010, **45**, 2405-2417; DOI:10.1016/j.ejmech.2010.02.022
- 5. Jäger A, Stefani V, Guterres S S and Pohlmann A R, *Int J Pharm.*, 2007, **338**, 297-305; DOI:10.1016/j.ijpharm.2007.01.051
- 6. Batista M F R, Susana P G, Costa M, Belsley M and Raposo M M, *Tetrahedron*, 2007, **63**, 9842-9849; DOI:10.1016/j.tet.2007.06.098
- 7. Nurulla I, Tanimoto A, Shiraishi K, Sasaki S and Yamamoto T, *Polymer*, 2002, **43**, 1287-1293; DOI:10.1016/S0032-3861(01)00681-4
- 8. Kamal Shah, Sumit Chhabra, Sushant K Shrivastava and Pradeep Mishra, *Med Chem Res.*, 2013, **22(11)**, 5077-5104; DOI:10.1007/s00044-013-0476-9
- 9. Wei-Ling Chang, Chin-Shiang Chang, Po-Cheng Chiang, Yunn-Fang Ho, Ju-Fang Liu,Kai-Wei Chang and Jih-Hwa Guh, *British J Pharmacol.*, 2010, **160**(7), 1677-1689; DOI:10.1111/j.1476-5381.2010.00832.x
- 10. Beaulieu C, Wang Z, Denis D, Greig G, Lamontagne S and Wang J, *Bioorg Med Chem Lett.*, 2004, **14(12)**, 3195-3199; DOI:10.1016/j.bmcl.2004.04.005
- (a) Thankamony M and Mohanan K, *Indian J Chem A*, 2007, 46(2), 247-251;
 (b) Patra A, Sarkar S, Drew M G B, Zangrando E and Chattopadhyay P, *Polyhedron*, 2009, 28(7), 1261-1264; DOI:10.1016/j.poly.2009.02.039
- 12. Raman N, Raja J D and Sakthivel A, *J Chem Sci.*, 2007, **119(4)**, 303-310; DOI:10.1007/s12039-007-0041-5

- 13. Arion V B, Reisner E, Fremuth M, Jokupec M A, Keppler B K, Kukushkin V Y and Pombeiro A J L, *J Inorg Biochem.*, 2003, **96(1)**, 95; DOI:10.1016/S0162-0134(03)80556-1
- 14. Shivakumar K and Halli M B, *J Coord Chem.*, 2006, **59(16)**, 1847-1856. DOI:10.1080/00958970600655548
- 15. Chandra S and Gupta L K, *Spectrochim Acta A*, 2004, **60**(7), 1563-1571; DOI:10.1016/j.saa.2004.01.015
- 16. Maurya R C, Malik B A, Mir J M and Vishwakarma P K, *J Mol Struct.*, 2015, **1083**, 343-356; DOI:10.1016/j.molstruc.2014.11.032
- 17. Denis P and Ventura O N, *J Mol Struct.*, 2001, **537(1-3)**, 173-180; DOI:10.1016/S0166-1280(00)00674-6
- 18. Abkowicz-Bienko A J, Bienko D C and Latajka Z, *J Mol Struct.*, 2000, **552(1-3)**, 165-175; DOI:10.1016/S0022-2860(00)00476-2
- Banclersen K, Langgard M and Sparget-Larsen J, J Mol Struct., 1999, 509(1-3), 153-163; DOI:10.1016/S0022-2860(99)00217-3
- 20. GaussView 5.0, Gaussian Inc., Garnegie Office, Park. Pittsburgh, PA, USA.
- 21. Morris G M, Huey R, Lindstrom W, Sanner M F, Belew R K, Goodsell D S and Olson A J, *J Computational Chem.*, 2009, **16**, 2785-91; DOI:10.1002/jcc.21256
- 22. Adebayo A Adeniyi and Peter A Ajibade, *Molecules*, 2013, **18**, 3760-3778; DOI:10.3390/molecules18043760
- 23. Graham Patrick, An Introduction to Medicinal Chemistry, 5th Edition, Oxford University Press, 2013.
- 24. Vogal A I, "A Textbook of Quantitative Inorganic Analysis" 33rd Edition, Londman, London, 1968, 264.
- 25. Abdel-Rahman L H, Abu-Dief A M, Newair E F and Hamdan S K, *J Photochem Photobiol B.*, 2016, **160**, 18-31; DOI:10.1016/j.jphotobiol.2016.03.040
- 26. Anjaneyulu, Y and Prabhakara Rao R, *Synth. React Inorg Met-Org Chem.*, 1986, **16**, 257-272; DOI:10.1080/00945718608057530
- Muniyandi V, Pravin N, Mitu L and Raman N, *J Mol Struct.*, 2015, **1086**, 56-63; DOI: 10.1016/j.molstruc.2015.01.011
- 28. M. Ozcan, I. Dehri, M. Erbil, Appl. Surf. Sci. 2004, 236, 155-164.
- Scrocco E and Tomasi J, Adv Quant Chem., 1979, 11, 115-193; DOI:10.1016/S0065-3276(08)60236-1
- 30. Luque F J, Lopez J M and Orozco M, *Theor Chem Acc.*, 2000, **103(3-4)**, 343-345; DOI:10.1007/978-3-662-10421-7_56
- 31. Okulik N and Jubert A H, Internet Electron J Mol Des., 2005, 4, 17-30.
- 32. Sun Y, Chen X, Sun L, Guo X and Lu W, *J Chem Phys Lett.*, 2003, **381(3-4)**, 397-403; DOI:10.1016/j.cplett.2003.09.115
- 33. Christiansen O, Gauss J, Stanton J F, J Chem Phys Lett., 1999, **305**, 147; DOI:10.1063/1.479332
- 34. Maurya R C, Malik B A, Mir J M, Vishwakarma P K, Rajak D K and Jain N, *J Coord Chem.*, 2015, 68 (16), 2902-2922; DOI:10.1080/00958972.2015.1064526
- 35. Searle M S, Maynard A J and Williams H E, *Org Biomol Chem.*, 2003, **1**(1), 60-66; DOI:10.1039/B208622K
- 36. Michel F Sanner, J Mol Graphics Mod., 1999, 17(1), 57-61